Incremental value of Alberta Stroke Program Early CT Score to collateral score for predicting target mismatch in stroke patients with extended time window or unknown onset time

Neurological Sciences - To evaluate whether Alberta Stroke Program Early CT Score (ASPECTS) could provide incremental value to collateral score, and their integration could be an effective...     

妊娠期顽固性肾绞痛的腔内处理

目的探讨腔内诊治妊娠期肾积水合并顽固性肾绞痛的安全性和有效性。 方法回顾性分析2017年3月至2018年9月我院收治的78例妊娠期肾积水合并顽固性肾绞痛患者的病例资料。根据顽固性肾绞痛持续时间将患者分为A组（6 h以内16例）,B组（6～12 h 53例）和C组（12 h以上9例）。 结果58例术中发现输尿管结石,16例（27.6%）术前彩超未见输尿管结石,行输尿管镜碎石取石和留置输尿管双J管。输尿管结石清除率87.9%（51/58）。20例未发现输尿管结石但合并肾盂结石患者,术中留置输尿管双J管。9例（11.5%）有先兆流产表现,其中A组1例（6.25%）,B组4例（7.55%）,C组4例（44.4%）。C组先兆流产的发生率高于A和B组（P<0.05）。1例（6.25%）患者出现尿源性脓毒血症,抗感染等对症处理后痊愈。所有患者均成功通过围产期并生产健康婴儿。 结论对于妊娠期肾积水合并顽固性肾绞痛的患者,早期输尿管镜腔内处理是有效安全的诊断和治疗手段,可降低孕妇和胎儿的风险。     

腹腔镜胰十二指肠切除术经验初探

目的 探讨腹腔镜胰十二指肠切除术（LPD）初期应用的可行性和安全性。方法 回顾性分析2018 年8 月至2019 年8 月徐州医科大学附属宿迁医院收治的10 例行LPD治疗的壶腹周围癌及胰头部良性或恶性肿瘤患者术中及术后临床资料。所有患者均由同一组手术医师采用“五孔法”经典路径行LPD。结果 所有患者均顺利完成LPD手术。平均手术时间（437.0±87.0）min,术中出血量（171.0±106.0）mL,均未输血。总体并发症发生率为40%（4/10）。患者术后（2.0±1.1）d下床活动,术后住院时间（15.0±2.0）d。术后发生胰瘘3 例,其中A级2 例,B级1 例;上消化道出血1 例。术后中位随访时间9（2～14）个月,期间无患者死亡,1 例发现肿瘤复发转移。结论 LPD创伤小,安全有效,术后恢复快,并发症发生率在可接受范围内,具有一定优势。应用开展初期通过病例选择循序渐进,具备一定腹腔镜手术技术和经验的术者开展LPD是安全可行的。     

Genetic variants of SDCCAG8 and MAGI2 in mitosis-related pathway genes are independent predictors of cutaneous melanoma-specific survival

Mitosis is a prognostic factor for cutaneous melanoma (CM), but accurate mitosis detection in CM tissues is difficult. Therefore, the 8th Edition of the American Joint Committee on Cancer staging system has removed the mitotic rate as a category criterion of the tumor T-category, based on the evidence that the mitotic rate was not an independent prognostic factor for melanoma survival. As single-nucleotide polymorphisms (SNPs) have been shown to be potential predictors for cutaneous melanoma-specific survival (CMSS), we investigated the potential prognostic value of SNPs in mitosis-related pathway genes in CMSS by analyzing their associations with outcomes of 850 CM patients from The University of Texas MD Anderson Cancer Center in a discovery dataset and validated the findings in another dataset of 409 CM patients from the Harvard University Nurses’ Health Study and Health Professionals Follow-up Study. In both datasets, we identified two SNPs (SDCCAG8 rs10803138 G>A and MAGI2 rs3807694 C>T) as independent prognostic factors for CMSS, with adjusted allelic hazards ratios of 1.49 (95% confidence interval = 1.17-1.90, P = .001) and 1.45 (1.13-1.86, P = .003), respectively. Furthermore, their combined unfavorable alleles also predicted a poor survival in both discovery and validation datasets in a dose-response manner (P_trend = .0006 and .0001, respectively). Additional functional analysis revealed that both SDCCAG8 rs10803138 A and MAGI2 rs3807694 T alleles were associated with elevated mRNA expression levels in normal tissues. Therefore, these findings suggest that SDCCAG8 rs10803138 G>A and MAGI2 rs3807694 C>T are independent prognostic biomarkers for CMSS, possibly by regulating the mRNA expression of the corresponding genes involved in mitosis.     

Curcumin analog B14 has high bioavailability and enhances the effect of anti‐breast cancer cells in vitro and in vivo

Curcumin has a variety of anticancer properties, but low bioavailability prevents its use in chemotherapeutic applications. To address this problem, we tested the efficacy of the synthetic curcumin analog B14 in breast cancer cells and explored the mechanism by which B14 inhibits proliferation and metastasis of breast cancer cells. We used the breast cancer cell line MCF‐7, MDA‐MB‐231 to study the anticancer effects of B14 and assessed cell viability, cell migration and invasion, cell cycle, and apoptosis, in addition, the antitumor effect of B14 in vivo was examined in mice bearing MDA‐MB‐231 cells. We found that, as the concentration of B14 increased, cell viability decreased in a dose‐dependent manner. Compound B14 exerted the best antitumor activity and selectivity for MCF‐7 and MDA‐M‐231 cells (IC₅₀ = 8.84 μmol/L and 8.33 μmol/L, respectively), while its IC₅₀ value for MCF‐10A breast epithelial cells was 34.96 μmol/L. B14 has been shown to be a multi‐targeted drug that alters the expression of cyclin D1, cyclin E1, and cyclin‐dependent kinase 2 (CDK2), and ultimately induces G1 phase cell cycle arrest. At the same time, B14 activates the mitochondrial apoptosis pathway in breast cancer cells. Furthermore, B14 was more effective than curcumin in inhibiting cell migration, invasion, and colony formation. In tumor‐bearing mice, analog B14 significantly reduced tumor growth and inhibited cell proliferation and angiogenesis. The pharmacokinetic test found that B14 was more stable than curcumin in vivo. Our data reveal the therapeutic potential of the curcumin analog B14 and the underlying mechanisms to fight breast cancer cells.     

新辅助治疗乳腺癌病人的心理干预

新辅助治疗（neoadjuvant chemotherapy）是术前化疗（preoperative chemotherapy）然后再手术治疗，是乳腺癌治疗方法之一。心理干预治疗是一项较新的心理治疗方法，将两者结合是护理管理的新尝试。由于接受新辅助治疗病人的心理变化复杂，有大量时间能平衡心理状态。心理干预有利于提高乳腺癌病人的NK细胞活性（NKCA）提高机体免疫功能。因此我们应用简便、可行和实用的心理行为干预方法，解决病人的实际问题，提高病人的治疗质量。同时推动肿瘤临床整体化护理管理的进展。     

丙戊酸对致死性失血性休克犬器官功能和预后的影响

目的 探讨组蛋白去乙酰化酶抑制剂丙戊酸(VPA)对致死性失血性休克犬器官功能和预后的影响.方法 20只成年雄性Beagle犬,采用颈总动脉放血(按全身血容量的42%计算)制备失血性休克模型.将模型犬按随机数字表法分为休克对照组和VPA治疗组,每组10只.VPA治疗组于失血后1.5 h静脉注射(静注)VPA 100 mg/kg(溶于20 ml生理盐水),休克对照组在失血后24 h内静注20 ml生理盐水;失血后24 h起两组犬均实施延迟静脉补液.在非麻醉状态下测定犬失血前(0 h)和失血后不同时间点平均动脉压(MAP)及血浆丙氨酸转氨酶(ALT)、肌酐(Cr)和肌酸激酶同工酶(CK-MB),记录尿量及72 h生存率.结果 两组失血后2 h MAP均显著降低;随后VPA治疗组MAP(mm Hg,1 mm Hg=0.133 kPa)迅速回升,于失血后4、8和24 h显著高于相应休克对照组(58.4±7.6比40.3±5.0,84.4±8.0比56.4±4.4,92.6±10.3比72.6±8.9,P＜0.05或P＜0.01).VPA治疗组0～8、8～24、24～48和48～72 h尿量均显著多于休克对照组,但仍显著少于失血前(0 h).两组失血后血浆ALT、Cr和CK-MB均较0 h显著升高;VPA治疗组失血后4 h起器官功能指标显著低于休克对照组[ALT(U/L):80.1±9.8比112.2±10.1;Cr(μmol/L):74.5±8.3比88.0±7.6;CK-MB(kU/L):10.39±1.10比13.67±1.46,P＜0.05或P＜0.01],但失血后72 h仍显著高于0 h(ALT:79.5±7.1比40.5±4.4;Cr:85.6±7.1比46.6±4.8;CK-MB:7.63±0.86比1.66±0.21,均P＜0.01).VPA治疗组失血后72 h生存率显著高于休克对照组[70%(7/10)比20%(2/10),P＜0.05].结论 犬42%血容量失血后静注VPA能有效提高MAP,增加尿量,减轻器官功能损害,提高72 h早期生存率,有潜力成为战争或突发事故及灾害时低血容量休克现场救治的有效药物.     

原发性纵隔肿瘤124例临床分析

目的:总结原发性纵隔肿瘤的诊治经验.方法:回顾性分析124例原发性纵隔肿瘤的临床资料.结果:根据病史、体格检查,结合X线胸片、胸部CT、磁共振成像等术前确诊98例(79.0%).手术治疗118例(95.2%)均获确诊,治愈110例(88 7%),死亡3例.随访期间无复发病例.结论:病史、体格检查与影像学检查相结合是原发性纵隔肿瘤的主要诊断手段;手术治疗是有效的治疗方法,尽早手术治疗效果良好.